XenoPort to Present at the Credit Suisse Healthcare Conference
October 29 2015 - 2:19PM
Business Wire
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will
provide access via the World Wide Web to its presentation at the
2015 Credit Suisse Healthcare Conference in Phoenix, Arizona. The
live presentation will occur at 9:30 a.m. Pacific Time (10:30 a.m.
Mountain Time) on Wednesday, November 11, 2015. A replay of the
presentation will also be available.
To access the live presentation via the Web, please go to
www.XenoPort.com. Please connect to the Website at least 15 minutes
prior to the live presentation to ensure adequate time for any
software downloads that may be necessary to listen to the
Webcast.
A replay of the Webcast can be accessed for a minimum of one
month and will be available approximately 24 hours after the live
presentation.
About XenoPort
XenoPort, Inc. is a biopharmaceutical company focused on
commercializing HORIZANT® (gabapentin enacarbil) Extended-Release
Tablets in the United States. XenoPort has entered into a clinical
trial agreement with the National Institute on Alcohol Abuse and
Alcoholism (NIAAA) under which the NIAAA has initiated a clinical
trial evaluating gabapentin enacarbil as a potential treatment for
AUD. REGNITE® (gabapentin enacarbil) Extended-Release Tablets is
being marketed in Japan by Astellas Pharma Inc. XenoPort has
granted exclusive world-wide rights for the development and
commercialization of its clinical-stage oral product candidate,
arbaclofen placarbil, to Indivior PLC for all indications.
XenoPort’s other product candidates include XP23829, a novel
fumaric acid ester prodrug that is a potential treatment for
patients with moderate-to-severe chronic plaque-type psoriasis or
patients with relapsing forms of multiple sclerosis, and XP21279, a
prodrug of levodopa that is a potential treatment for patients with
idiopathic Parkinson's disease.
To learn more about XenoPort, please visit the Website at
www.XenoPort.com.
HORIZANT, REGNITE and XENOPORT are registered trademarks of
XenoPort, Inc.
XNPT2G
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151029006472/en/
XenoPort, Inc.Jackie Cossmon, 408-616-7220ir@XenoPort.com
Xenoport, Inc. (NASDAQ:XNPT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Xenoport, Inc. (NASDAQ:XNPT)
Historical Stock Chart
From Sep 2023 to Sep 2024